TWI776821B - α-V β-6整合素配位子 - Google Patents
α-V β-6整合素配位子 Download PDFInfo
- Publication number
- TWI776821B TWI776821B TW106137824A TW106137824A TWI776821B TW I776821 B TWI776821 B TW I776821B TW 106137824 A TW106137824 A TW 106137824A TW 106137824 A TW106137824 A TW 106137824A TW I776821 B TWI776821 B TW I776821B
- Authority
- TW
- Taiwan
- Prior art keywords
- xaa
- misc
- feature
- αvβ6 integrin
- integrin ligand
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 89
- 108010021309 integrin beta6 Proteins 0.000 title description 2
- 108010044426 integrins Proteins 0.000 claims abstract description 66
- 102000006495 integrins Human genes 0.000 claims abstract description 66
- 239000000203 mixture Substances 0.000 claims abstract description 9
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 62
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 33
- 229920001223 polyethylene glycol Polymers 0.000 claims description 28
- 108090000765 processed proteins & peptides Chemical class 0.000 claims description 27
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims description 22
- 229920000642 polymer Chemical class 0.000 claims description 19
- 108010077895 Sarcosine Proteins 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000005647 linker group Chemical group 0.000 claims description 13
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 108090000623 proteins and genes Chemical class 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 claims description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 6
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 229960003767 alanine Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 5
- 235000013477 citrulline Nutrition 0.000 claims description 5
- 229960002173 citrulline Drugs 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
- 108091030071 RNAI Proteins 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000009368 gene silencing by RNA Effects 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 229920000768 polyamine Chemical class 0.000 claims description 3
- 108091033319 polynucleotide Chemical class 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Chemical class 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 239000003053 toxin Chemical class 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 239000011782 vitamin Chemical class 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229930003231 vitamin Chemical class 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 2
- 101150065749 Churc1 gene Proteins 0.000 claims 2
- 102100038239 Protein Churchill Human genes 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 108091023037 Aptamer Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108700012359 toxins Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 18
- 229940024606 amino acid Drugs 0.000 description 77
- 235000001014 amino acid Nutrition 0.000 description 75
- 150000001413 amino acids Chemical class 0.000 description 69
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 59
- 150000007649 L alpha amino acids Chemical class 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 33
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 19
- 229960003136 leucine Drugs 0.000 description 15
- 230000027455 binding Effects 0.000 description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000004395 L-leucine Substances 0.000 description 10
- 235000019454 L-leucine Nutrition 0.000 description 10
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
- -1 N-methylglycine Amino acid Chemical class 0.000 description 8
- 229940049906 glutamate Drugs 0.000 description 8
- 229930195712 glutamate Natural products 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 229940009098 aspartate Drugs 0.000 description 7
- 229960002989 glutamic acid Drugs 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 6
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 6
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- CWAYDJFPMMUKOI-YFKPBYRVSA-N (2s)-2-amino-2-methylbutanedioic acid Chemical compound OC(=O)[C@](N)(C)CC(O)=O CWAYDJFPMMUKOI-YFKPBYRVSA-N 0.000 description 5
- NWGZOALPWZDXNG-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(dimethylamino)pentanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCNC(N)=N NWGZOALPWZDXNG-LURJTMIESA-N 0.000 description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229960002429 proline Drugs 0.000 description 5
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- ARSWQPLPYROOBG-ZETCQYMHSA-N 2-methylleucine Chemical compound CC(C)C[C@](C)(N)C(O)=O ARSWQPLPYROOBG-ZETCQYMHSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 229960005261 aspartic acid Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 3
- DATPFTPVGIHCCM-BYPYZUCNSA-N (2s)-2-(ethylamino)propanoic acid Chemical compound CCN[C@@H](C)C(O)=O DATPFTPVGIHCCM-BYPYZUCNSA-N 0.000 description 3
- NEEQFPMRODQIKX-UHFFFAOYSA-N (S)-Dencichine Natural products OC(=O)C(N)CNC(=O)C(O)=O NEEQFPMRODQIKX-UHFFFAOYSA-N 0.000 description 3
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 3
- RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 3
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 101000999322 Homo sapiens Putative insulin-like growth factor 2 antisense gene protein Proteins 0.000 description 3
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 3
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 102100036485 Putative insulin-like growth factor 2 antisense gene protein Human genes 0.000 description 3
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 3
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 3
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229960002433 cysteine Drugs 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- GCHPUFAZSONQIV-UHFFFAOYSA-N isovaline Chemical compound CCC(C)(N)C(O)=O GCHPUFAZSONQIV-UHFFFAOYSA-N 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 3
- 235000016491 selenocysteine Nutrition 0.000 description 3
- 229940055619 selenocysteine Drugs 0.000 description 3
- 229960002718 selenomethionine Drugs 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- GLJCJFFDYXFRQX-NRFANRHFSA-N (2s)-3-(2,4-dinitroanilino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GLJCJFFDYXFRQX-NRFANRHFSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 102000019198 CapZ Actin Capping Protein Human genes 0.000 description 2
- 108010012892 CapZ Actin Capping Protein Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000001314 canonical amino-acid group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HJHSDOOIPJGRSK-QMMMGPOBSA-N (2s)-2-(hexylamino)propanoic acid Chemical compound CCCCCCN[C@@H](C)C(O)=O HJHSDOOIPJGRSK-QMMMGPOBSA-N 0.000 description 1
- VRTVCGMQWXYEIZ-BYPYZUCNSA-N (2s)-5-(diaminomethylideneamino)-2-[2-(diaminomethylidene)hydrazinyl]pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NNC(N)=N VRTVCGMQWXYEIZ-BYPYZUCNSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000001431 2-aminoisobutyric acid group Chemical group [#6]C([#6])(N*)C(*)=O 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- LFYYSOLRUWYAPN-UHFFFAOYSA-N 2-ethoxyethanamine prop-2-enoic acid Chemical compound OC(=O)C=C.CCOCCN LFYYSOLRUWYAPN-UHFFFAOYSA-N 0.000 description 1
- STUCMBRFCQKITK-UHFFFAOYSA-N 3-(diaminomethylideneamino)benzoic acid Chemical compound NC(N)=NC1=CC=CC(C(O)=O)=C1 STUCMBRFCQKITK-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108010024636 Glutathione Chemical class 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 125000002832 L-alpha-aminobutyric acid group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical group OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- PSVXZQVXSXSQRO-UHFFFAOYSA-N undecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO PSVXZQVXSXSQRO-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本文闡述具有血清穩定性且對於αvβ6整合素具有親和性之αvβ6整合素配位子。本文亦闡述包含具有血清穩定性且對於αvβ6整合素具有親和性之αvβ6整合素配位子之組合物。
Description
在上皮細胞中表現之整合素αvβ6係TGF-β之隱性相關肽(LAP)及(ECM)蛋白(纖連蛋白、玻連蛋白及生腱蛋白)之受體。 αvβ6儘管在正常健康成人上皮細胞中幾乎不可檢測，但在傷口癒合期間及不同癌症(結腸、卵巢、子宮內膜及胃)中經上調，且通常與差的癌症預後相關。經顯示其在轉移中促進細胞入侵及遷移，並抑制細胞凋亡。αvβ6亦可調節基質金屬蛋白酶(MMP)之表現並活化TGF-β1。主要來自活體外研究之日益增加之證據表明αvβ6可實際上促進癌進展。此整合素作為腫瘤生物標記物及潛在治療靶點且對於其表現基質金屬蛋白酶(MMP)並活化TGF-β1之作用具有吸引力。
本文闡述αvβ6整合素配位子(亦稱為αvβ6配位子)。αvβ6整合素配位子包含通式：ZRGDLXaa1
Xaa2
LYR1
，其中Z係如本文所述之胺端帽，R係L-精胺酸。G係L-甘胺酸或N-甲基甘胺酸，D係L-天冬胺酸(L-天冬胺酸鹽)，L係L-白胺酸，Xaa1
及Xaa2
獨立地係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸，Y可選且若存在，則可含有一或多種L-α胺基酸、L-β-胺基酸或α,α-二取代之胺基酸及/或連接基團，且R1
可選且若存在，則包含聚乙二醇。αvβ6整合素配位子在血清中穩定且對於αvβ6整合素具有親和性或與其結合。本文進一步闡述含有αvβ6整合素配位子之組合物及使用所述αvβ6整合素配位子之方法。在一些實施例中，Z-R可經R'替代，其中R'係Dap (胍基)。 在一些實施例中，αvβ6配位子連接至貨物分子、反應性基團或受保護之反應性基團。反應性基團可用於促進αvβ6配位子偶聯至分子，例如貨物分子。αvβ6可增加貨物分子靶向αvβ6整合素或表現αvβ6整合素之細胞。貨物分子可係(但不限於)醫藥成分、藥物產品、前藥、有治療價值之物質、小分子、抗體、抗體片段、免疫球蛋白、單株抗體、標記或標記物、脂質、天然或經修飾之核酸或多核苷酸、肽、聚合物、多胺、蛋白質、毒素、維生素、PEG、半抗原、地谷新配質(digoxigenin)、生物素、放射性原子或分子或螢光團。 本文闡述所述αvβ6配位子使貨物分子靶向表現αvβ6之細胞之用途。細胞可為活體外、原位、離體或活體內。 本文闡述含有一或多種αvβ6配位子之組合物。在一些實施例中，組合物進一步包含醫藥上可接受之賦形劑。在一些實施例中，組合物進一步包含一或多種其他有治療價值之物質。 本文闡述含有一或多種αvβ6配位子之藥劑以及製造此等藥劑之方法。在一些實施例中，藥劑進一步包含醫藥上可接受之賦形劑。所述方法包含使一或多種αvβ6配位子及(若期望)一或多種其他有治療價值之物質形成蓋侖製劑(galenical)投與形式。 在一些實施例中闡述用於將RNAi觸發因子活體內遞送至細胞之組合物。
本文闡述具有血清穩定性且對於αvβ6整合素具有親和性之αvβ6整合素配位子。αvβ6整合素配位子可用於活體外、原位、離體及/或活體內靶向表現αvβ6整合素之細胞。 在一些實施例中闡述αvβ6整合素配位子，其包含： Z-RGDLX1
X2
L (式I) 其中 Z係胺端帽， R係L-精胺酸， G係L-甘胺酸或N-甲基甘胺酸， D係L-天冬胺酸(L-天冬胺酸鹽)， L係L-白胺酸， Xaa1
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸，且 Xaa2
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸。 在一些實施例中，L經由醯胺鍵連接至Y。 在一些實施例中闡述αvβ6整合素配位子，其包含： R'GDLX1
X2
L (式Ia) 其中 R'係Dap (胍基)， G係L-甘胺酸或N-甲基甘胺酸， D係L-天冬胺酸(L-天冬胺酸鹽)， L係L-白胺酸， Xaa1
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸，且 Xaa2
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸。 在一些實施例中，L經由醯胺鍵連接至Y。 在一些實施例中闡述αvβ6整合素配位子，其包含： Z-RGDLXaa1
Xaa2
L-Y-R1
(式II) 其中 Z係胺端帽， R係L-精胺酸， G係L-甘胺酸或N-甲基甘胺酸， D係L-天冬胺酸(L-天冬胺酸鹽)， L係L-白胺酸， Xaa1
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸， Xaa2
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸， Y可選且若存在，則含有一或多種L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸及/或連接基團，且 R1
可選且若存在，則包含聚乙二醇(PEG)。 在一些實施例中，L經由醯胺鍵連接至Y。 在一些實施例中闡述αvβ6整合素配位子，其包含： R'GDLXaa1
Xaa2
L-Y-R1
(式IIa) 其中 R'係Dap (胍基)， G係L-甘胺酸或N-甲基甘胺酸， D係L-天冬胺酸(L-天冬胺酸鹽)， L係L-白胺酸， Xaa1
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸， Xaa2
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸， Y可選且若存在，則含有一或多種L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸及/或連接基團，且 R1
可選且若存在，則包含聚乙二醇(PEG)。 在一些實施例中，L經由醯胺鍵連接至Y。 在一些實施例中闡述具有反應性基團之αvβ6整合素配位子，其包含： Z-RGDLXaa1
Xaa2
L-Y-R1
-R2
(式III) 其中 Z係胺端帽， R係L-精胺酸， G係L-甘胺酸或N-甲基甘胺酸， D係L-天冬胺酸(L-天冬胺酸鹽)， L係L-白胺酸， Xaa1
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸，且 Xaa2
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸， Y可選且若存在，則含有一或多種L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸及/或連接基團， R1
可選且若存在，則包含聚乙二醇(PEG)，且 R2
包含反應性基團或受保護之反應性基團。 反應性基團或受保護之反應性基團可用於使αvβ6整合素配位子附接至所關注之分子。在一些實施例中，L經由醯胺鍵連接至Y。 在一些實施例中闡述具有反應性基團之αvβ6整合素配位子，其包含： R'GDLXaa1
Xaa2
L-Y-R1
-R2
(式IIIa) 其中 R'係Dap (胍基)， G係L-甘胺酸或N-甲基甘胺酸， D係L-天冬胺酸(L-天冬胺酸鹽)， L係L-白胺酸， Xaa1
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸，且 Xaa2
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸， Y可選且若存在，則含有一或多種L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸及/或連接基團， R1
可選且若存在，則包含聚乙二醇(PEG)，且 R2
包含反應性基團或受保護之反應性基團。 反應性基團或受保護之反應性基團可用於使αvβ6整合素配位子附接至所關注之分子。在一些實施例中，L經由醯胺鍵連接至Y。 在一些實施例中闡述αvβ6整合素配位子-貨物分子偶聯物，其包含： (Z-RGDLXaa1
Xaa2
L-Y-R1
)n
-R3
(式IV) 其中 Z係胺端帽， R係L-精胺酸， G係L-甘胺酸或N-甲基甘胺酸， D係L-天冬胺酸(L-天冬胺酸鹽)， L係L-白胺酸， Xaa1
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸，且 Xaa2
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸， Y可選且若存在，則係一或多種L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸及/或連接基團， R1
可選且若存在，則包含聚乙二醇， n係大於0之整數，且 R3
包含貨物分子。 在一些實施例中，L經由醯胺鍵連接至Y。貨物分子可係期望靶向表現αvβ6整合素之細胞之任何分子。 在一些實施例中闡述αvβ6整合素配位子-貨物分子偶聯物，其包含： (R'GDLXaa1
Xaa2
L-Y-R1
)n
-R3
(式IVa) 其中 R'係Dap (胍基)， G係L-甘胺酸或N-甲基甘胺酸， D係L-天冬胺酸(L-天冬胺酸鹽)， L係L-白胺酸， Xaa1
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸，且 Xaa2
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸， Y可選且若存在，則係一或多種L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸及/或連接基團， R1
可選且若存在，則包含聚乙二醇， n係大於0之整數，且 R3
包含貨物分子。 在一些實施例中，L經由醯胺鍵連接至Y。貨物分子可係期望靶向表現αvβ6整合素之細胞之任何分子。 胺端帽Z包含化學部分，其增加或改良RGDLXaa1
Xaa2
L肽之蛋白酶抗性及/或血清穩定性特徵。在一些實施例中，Z包含RGDLXaa1
Xaa2
L肽之N-末端胺之蛋白酶抗性醯化或烷基化。在一些實施例中，胺端帽Z可係(但不限於) CH3
CO、CH3
CH2
CO、CH3
(CH2
)2
CO、CH3
(CH2
)3
CO、CH3
(CH2
)4
CO、具有1、2、3、4、5、6、7、8、9或10個碳原子之烷基、甲基、乙基、丙基、丁基、戊基、NH2
NH、PEG、胍基、CH3
OCH2
CH2
OCH2
CH2
CO、CH3
O(CH2
CH2
O)2
CH2
CH2
CO、CH3
O(CH2
CH2
O)3
CH2
CH2
CO、CH3
O(CH2
CH2
O)4
CH2
CH2
CO、CH3
O(CH2
CH2
O)5
CH2
CH2
CO、CH3
OCH2
CH2
OCH2
CO、CH3
O(CH2
CH2
O)2
CH2
CO、CH3
O(CH2
CH2
O)3
CH2
CO、CH3
O(CH2
CH2
O)4
CH2
CO、CH3
O(CH2
CH2
O)5
CH2
CO、CH3
OCH2
CH2
OCO、CH3
O(CH2
CH2
O)2
CO、CH3
O(CH2
CH2
O)3
CO、CH3
O(CH2
CH2
O)4
CO、CH3
O(CH2
CH2
O)5
CO、HOCH2
CH2
OCH2
CH2
CO、HO(CH2
CH2
O)2
CH2
CH2
CO、HO(CH2
CH2
O)3
CH2
CH2
CO、HO(CH2
CH2
O)4
CH2
CH2
CO、HO(CH2
CH2
O)5
CH2
CH2
CO、HOCH2
CH2
OCH2
CO、HO(CH2
CH2
O)2
CH2
CO、HO(CH2
CH2
O)3
CH2
CO、HO(CH2
CH2
O)4
CH2
CO、HO(CH2
CH2
O)5
CH2
CO、HOCH2
CH2
OCO、HO(CH2
CH2
O)2
CO、HO(CH2
CH2
O)3
CO、HO(CH2
CH2
O)4
CO、HO(CH2
CH2
O)5
CO、CH3
CH2
OCH2
CH2
OCH2
CH2
CO、CH3
CH2
O(CH2
CH2
O)2
CH2
CH2
CO、CH3
CH2
O(CH2
CH2
O)3
CH2
CH2
CO、CH3
CH2
O(CH2
CH2
O)4
CH2
CH2
CO、CH3
CH2
O(CH2
CH2
O)5
CH2
CH2
CO、CH3
CH2
OCH2
CH2
OCH2
CO、CH3
CH2
O(CH2
CH2
O)2
CH2
CO、CH3
CH2
O(CH2
CH2
O)3
CH2
CO、CH3
CH2
O(CH2
CH2
O)4
CH2
CO、CH3
CH2
O(CH2
CH2
O)5
CH2
CO、CH3
CH2
OCH2
CH2
OCO、CH3
CH2
O(CH2
CH2
O)2
CO、CH3
CH2
O(CH2
CH2
O)3
CO、CH3
CH2
O(CH2
CH2
O)4
CO、CH3
CH2
O(CH2
CH2
O)5
CO、CH3
OCH2
CH2
CO、HOCH2
CH2
CO或CH3
CH2
OCH2
CH2
CO。 在一些實施例中，Xaa1
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸。Xaa1
可係(但不限於)天然L-α胺基酸、天然蛋白胺基酸、天然標準(即，由通用遺傳密碼之密碼子直接編碼之20個胺基酸，亦稱為經典胺基酸之經編碼胺基酸)胺基酸或非天然(亦稱為非標準、非編碼或非經典)胺基酸。標準胺基酸包括丙胺酸、半胱胺酸、天冬胺酸(天冬胺酸鹽)、麩胺酸(麩胺酸鹽)、苯丙胺酸、甘胺酸、組胺酸、異白胺酸、離胺酸、白胺酸、甲硫胺酸、天冬醯胺酸、脯胺酸、麩醯胺酸、精胺酸、絲胺酸、蘇胺酸、纈胺酸、色胺酸、酪胺酸。非標準胺基酸包括(但不限於)硒代半胱胺酸、吡咯離胺酸、N-甲醯基甲硫胺酸、羥脯胺酸、硒代甲硫胺酸、α-胺基-異丁酸(Aib)、α-胺基-丁酸(Abu)、α,g-二胺基丁酸、去氫丙胺酸、正白胺酸、別異白胺酸、第三白胺酸、α-胺基-正庚酸、α,β-二胺基丙酸、β-N-草醯基-α,β-二胺基丙酸、別蘇胺酸、高半胱胺酸、高絲胺酸、β-高丙胺酸(β3-hA)、異纈胺酸、正纈胺酸(Nva)、瓜胺酸(Cit)、鳥胺酸、α-甲基-天冬胺酸鹽(αMeD)、α-甲基-白胺酸(αMeL)、N-甲基丙胺酸、N-甲基-甘胺酸(NMe
G)、N-甲基白胺酸(NMe
L)、β-環己基-丙胺酸(Cha)、N-乙基丙胺酸、N,N-ε-二甲基離胺酸(K(Me
)2
)、二甲基精胺酸(R(Me)2
)、Dap (Ac)、n-烷基化之L-α胺基酸及以與天然胺基酸相似之方式起作用之其他胺基酸類似物或胺基酸模擬物。 在一些實施例中，Xaa2
係L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸。Xaa2
可係(但不限於)天然L-α胺基酸、天然蛋白胺基酸、天然標準(即，由通用遺傳密碼之密碼子直接編碼之20個胺基酸，亦稱為經典胺基酸之經編碼胺基酸)胺基酸或非天然(亦稱為非標準、非編碼或非經典)胺基酸。標準胺基酸包括丙胺酸、半胱胺酸、天冬胺酸(天冬胺酸鹽)、麩胺酸(麩胺酸鹽)、苯丙胺酸、甘胺酸、組胺酸、異白胺酸、離胺酸、白胺酸、甲硫胺酸、天冬醯胺酸、脯胺酸、麩醯胺酸、精胺酸、絲胺酸、蘇胺酸、纈胺酸、色胺酸、酪胺酸。非標準胺基酸包括(但不限於)硒代半胱胺酸、吡咯離胺酸、N-甲醯基甲硫胺酸、羥脯胺酸、硒代甲硫胺酸、α-胺基-異丁酸(Aib)、L-α-胺基-丁酸(Abu)、α,g-二胺基丁酸、去氫丙胺酸、正白胺酸、別異白胺酸、第三白胺酸、α-胺基-正庚酸、α,β-二胺基丙酸、β-N-草醯基-α,β-二胺基丙酸、別蘇胺酸、高半胱胺酸、高絲胺酸、β-高丙胺酸(β3-hA)、異纈胺酸、正纈胺酸(Nva)、瓜胺酸(Cit)、鳥胺酸、α-甲基-天冬胺酸鹽(αMeD)、α-甲基-白胺酸(αMeL)、N-甲基丙胺酸、N-甲基-甘胺酸(NMe
G)、N-甲基白胺酸(NMe
L)、β-環己基-丙胺酸(Cha)、N-乙基丙胺酸、N,N-ε-二甲基離胺酸(K(Me
)2
)、二甲基精胺酸(R(Me)2
)、Dap (Ac)、n-烷基化之L-α胺基酸及以與天然胺基酸相似之方式起作用之其他胺基酸類似物或胺基酸模擬物。 在一些實施例中，Xaa1
或Xaa2
係非標準胺基酸。在一些實施例中，Xaa1
係非標準胺基酸。在一些實施例中，Xaa2
係非標準胺基酸。在一些實施例中，Xaa1
及Xaa2
二者皆係非標準胺基酸。 在一些實施例中，Xaa1
及/或Xaa2
係Abu。在一些實施例中，Xaa1
係Abu。在一些實施例中，Xaa2
係Abu。 在一些實施例中，Xaa1
或Xaa2
不帶電。在一些實施例中，Xaa1
不帶電。在一些實施例中，Xaa2
不帶電。在一些實施例中，Xaa1
及Xaa2
不帶電。 在一些實施例中，Xaa1
不帶電且Xaa2
係非標準胺基酸。在一些實施例中，Xaa2
不帶電且Xaa1
係非標準胺基酸。在一些實施例中，Xaa1
不帶電且Xaa2
係Abu。在一些實施例中，Xaa2
不帶電且Xaa2
係Abu。 在一些實施例中，Xaa1
Xaa2
係AAbu、KAbu、EAbu、FAbu、QAbu、GAbu、PAbu、AK、AE、AF、AQ、AG及AP，其中A係L-丙胺酸，Abu係L-α-胺基丁酸，K係L-離胺酸，E係L-麩胺酸(麩胺酸鹽)，F係L-苯丙胺酸，Q係L-麩醯胺酸，G係L-甘胺酸且P係L-脯胺酸。 在一些實施例中，RGDLXaa1
Xaa2
L選自包含以下之群：RGDLAAbuL、RGDLKAbuL、RGDLEAbuL、RGDLFAbuL、RGDLQAbuL、RGDLGAbuL、RGDLPAbuL、RGDLAKL、RGDLAEL、RGDLAFL、RGDLAQL、RGDLAGL及RGDLAPL，其中R係L-精胺酸，G係L-甘胺酸或N-甲基甘胺酸，D係L-天冬胺酸(天冬胺酸鹽)，L係L-白胺酸，A係L-丙胺酸，Abu係L-α-胺基丁酸，K係L-離胺酸，E係L-麩胺酸(麩胺酸鹽)，F係L-苯丙胺酸，Q係L-麩醯胺酸且P係L-脯胺酸。 在一些實施例中，Y包含一種、兩種、三種或更多種L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸。在一些實施例中，Y包含一種、兩種、三種或更多種L-α胺基酸、L-β胺基酸或α,α-二取代之胺基酸及另外連接基團。在一些實施例中，Y包含連接基團。一種、兩種、三種或更多種胺基酸獨立地係天然L-α胺基酸、天然蛋白胺基酸、天然標準(即由通用遺傳密碼之密碼子直接編碼之20個胺基酸，亦稱為經典胺基酸之編碼胺基酸)胺基酸或非天然(亦稱為非標準、非編碼或非經典)胺基酸。標準胺基酸包括丙胺酸、半胱胺酸、天冬胺酸(天冬胺酸鹽)、麩胺酸(麩胺酸鹽)、苯丙胺酸、甘胺酸、組胺酸、異白胺酸、離胺酸、白胺酸、甲硫胺酸、天冬醯胺酸、脯胺酸、麩醯胺酸、精胺酸、絲胺酸、蘇胺酸、纈胺酸、色胺酸、酪胺酸。非標準胺基酸包括(但不限於)硒代半胱胺酸、吡咯離胺酸、N-甲醯基甲硫胺酸、羥脯胺酸、硒代甲硫胺酸、α-胺基-異丁酸(Aib)、L-α-胺基-丁酸(Abu)、α,g-二胺基丁酸、去氫丙胺酸、正白胺酸、別異白胺酸、第三白胺酸、α-胺基-正庚酸、α,β-二胺基丙酸、β-N-草醯基-α,β-二胺基丙酸、別蘇胺酸、高半胱胺酸、高絲胺酸、β-高丙胺酸(β3-hA)、異纈胺酸、正纈胺酸(Nva)、瓜胺酸(Cit)、鳥胺酸、α-甲基-天冬胺酸鹽(αMeD)、α-甲基-白胺酸(αMeL)、N-甲基丙胺酸、N-甲基-甘胺酸(NMe
G)、N-甲基白胺酸(NMe
L)、β-環己基-丙胺酸(Cha)、N-乙基丙胺酸、N,N-ε-二甲基離胺酸(K(Me
)2
)、二甲基精胺酸(R(Me)2
)、Dap (Ac)、n-烷基化之L-α胺基酸，及以與天然胺基酸相似之方式起作用之其他胺基酸類似物或胺基酸模擬物。在一些實施例中，Y含有至少一種非標準胺基酸。在一些實施例中，Y係Aib、Cit、CitAib、CitAibL、CitE、CitF、CitG、CitK、CitP、CitQ、CitQL、EAib、FAib、KAib、PAib、QAib、RabuL、RAibL、RCitL、RDap (Ac)L、RLQ或RNvaL。在一些實施例中，Y包含Aib、Cit、CitAib、CitAibL、CitE、CitF、CitG、CitK、CitP、CitQ、CitQL、EAib、FAib、KAib、PAib、QAib、RabuL、RAibL、RCitL、RDap (Ac)L、RLQ或RNvaL。 連接基團係將一個分子或分子之一部分連接至另一分子或分子之第二部分之一或多個原子。在業內，連接基團與間隔體有時可互換使用。 在一些實施例中，R1
存在且包含具有1-100個環氧乙烷(CH2
-CH2
-O)單元之PEG基團。在一些實施例中，R1
存在且包含具有2-20個環氧乙烷單元之PEG基團。在一些實施例中，R1
存在且包含具有2-10個環氧乙烷單元之PEG基團。在一些實施例中，R1
存在且包含具有2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19或20個環氧乙烷單元之PEG基團。 反應性基團在業內眾所周知且提供兩個分子或反應物之間之共價鍵聯之形成。受保護之反應性基團在業內亦常用。保護基團提供反應性基團向在不受保護基團反應之條件下不反應之基團之臨時化學轉變，以(例如)在隨後化學反應中提供化學選擇性。 貨物分子係可期望其靶向αvβ6整合素或表現αvβ6整合素之細胞之任一分子。貨物分子可係(但不限於)醫藥成分、藥物產品、前藥、有治療價值之物質、小分子、抗體、抗體片段、免疫球蛋白、單株抗體、標記或標記物、脂質、天然或經修飾之核酸或多核苷酸、肽、聚合物、多胺、蛋白質、毒素、維生素、PEG、半抗原、地谷新配質、生物素、放射性原子或分子或螢光團。 在一些實施例中，αvβ6整合素配位子包含由以下表示之結構：
式(V)， 其中Z包含如所述之胺端帽，且R2
及R3
分別係胺基酸Xaa1
及Xaa2
之側鏈。 所述之αvβ6整合素配位子包括其鹽或溶劑合物。αvβ6配位子之溶劑合物意指惰性溶劑分子與αvβ6整合素配位子由於其相互吸引力而形成之加和物。溶劑合物係(例如)單-或二水合物或與醇(例如，與甲醇或乙醇)之加成化合物。 可提供游離胺基或游離羥基作為具有相應保護基團之αvβ6整合素配位子之取代基。 αvβ6整合素配位子亦包括衍生物，即經(例如)烷基或醯基、糖或寡肽修飾之αvβ6整合素配位子，其在活體外或在生物體內經解離。 所述αvβ6配位子與親本αvβ6整合素結合肽RGDLATLRQL相比具有增加之血清穩定性。若在37℃下在小鼠血漿中培育12小時後仍藉由HLPC檢測到αvβ6配位子，則如本文所使用之αvβ6配位子展現大於20%、大於30%、大於40%、大於50%、大於60%、大於70%、大於80%或大於90%之增加之血清穩定性。 基於肽之藥物之重大問題係差的藥物動力學。許多肽由於酶催降解在血液中循環不超過幾分鐘，由此阻止其用作治療劑。多種血清製劑中之穩定性研究(量測血清及/或血漿中肽之活體外降解)在基於肽之藥物發展中已成為重要的篩選分析。在37℃下在小鼠血漿中培育4 h後，僅約5%之RGDLATLRQL可檢測到。在37℃下在小鼠血漿中8 h後，親本肽不可檢測。相比之下，在37℃下在小鼠血漿中12 h後，多於20%、多於30%、多於40%、多於50%、多於60%、多於70%、多於80%或多於90%之所述αvβ6配位子保留。所述αvβ6配位子儘管具有增加之血清穩定性，但保持結合至αvβ6整合素(對其具有親和性)。 醫藥組合物 在一些實施例中闡述醫藥組合物，其包含一或多種αvβ6配位子。如本文所使用，「醫藥組合物」包含藥理學上有效量之活性醫藥成分(API)及視情況一或多種醫藥上可接受之賦形劑。醫藥上可接受之賦形劑(賦形劑)係除API以外之物質，已經適當評估安全性且有意地包括在藥物遞送系統中。賦形劑在預期劑量下不發揮或不意欲發揮治療效應。賦形劑可用於a)在製造期間協助處理藥物遞送系統；b)保護、支持或增強API之穩定性、生物利用度或患者可接受度；c)協助產品鑑別，及/或d)在儲存或使用期間增強API之總體安全性、有效性、遞送之任何其他屬性。 賦形劑包括(但不限於)：吸收促進劑、抗黏著劑、消泡劑、抗氧化劑、黏合劑、緩衝劑、載劑、包衣劑、顏色、遞送增強劑、遞送聚合物、聚葡萄糖、右旋糖、稀釋劑、崩解劑、乳化劑、增量劑、填充劑、矯味劑、助流劑、保濕劑、潤滑劑、油、聚合物、防腐劑、鹽水、鹽、溶劑、糖、懸浮劑、持續釋放基質、甜味劑、增稠劑、張力劑、媒劑、防水劑及潤濕劑。 本文所述之醫藥組合物可含有在醫藥組合物中常見之其他另外組分。在一些實施例中，另外組分係醫藥活性物質。醫藥活性物質包括(但不限於)：止癢劑、收斂劑、局部麻醉劑或抗發炎劑(例如抗組織胺、苯海拉明(diphenhydramine)等)、小分子藥物、抗體、抗體片段及/或疫苗。 醫藥組合物亦可含有防腐劑、增溶劑、穩定劑、潤濕劑、乳化劑、甜味劑、著色劑、氣味劑、用於改變滲透壓之鹽、緩衝液、包衣劑或抗氧化劑。其亦可含有其他有治療價值之劑。 端視期望局部或全身性治療及欲治療區域，醫藥組合物可以多種方式投與。投與可藉由業內眾所周知之任何方式進行，例如(但不限於)局部(例如藉由經皮貼劑)、肺(例如藉由吸入或吹入粉末或氣溶膠，包括藉由霧化器、氣管內、鼻內)、表皮、經皮、經口或非經腸。非經腸投與包括(但不限於)靜脈內、動脈內、皮下、腹膜內或肌內注射或輸注；皮下(例如經由植入裝置)、顱內、實質內、鞘內及室內投與。在一些實施例中，本文所述之醫藥組合物係藉由皮下注射投與。醫藥組合物可以例如錠劑、包衣錠劑、糖衣錠、硬或軟明膠膠囊、溶液、乳液或懸浮液之形式經口投與。投與亦可經直腸實施，例如使用栓劑；局部或經皮實施，例如使用軟膏、乳膏、凝膠或溶液；或非經腸實施，例如使用可注射溶液。 含有αvβ6配位子之藥劑及製造此等藥劑之方法亦係本發明之目標，該等方法包含使一或多種含有αvβ6配位子之化合物及(若期望)一或多種其他有治療價值之物質形成蓋侖製劑投與形式。 細胞及組織及非人類生物體 本文涵蓋包括至少一種本文所述之αvβ6配位子之細胞、組織及非人類生物體。該細胞、組織或非人類生物體係藉由以業內可用之任何方式將αvβ6配位子遞送至細胞、組織或非人類生物體而製得。在一些實施例中，細胞係哺乳動物細胞，包括(但不限於)人類細胞。 所述αvβ6配位子及包含本文所揭示之αvβ6配位子之醫藥組合物可經包裝或包括在套組、容器、包裝或分配器中。αvβ6配位子及包含αvβ6配位子之醫藥組合物可包裝在預填充注射器或小瓶中。 現以下列非限制性實例闡釋上文所提供之實施例及條目。 實例實例 1. 配位子之合成 .
將Chem-Matrix Rink Amide樹脂置於燒結聚丙烯注射器中並在使用之前在DCM中攪動30分鐘。使用下列標準固相肽合成條件。藉由每1毫莫耳樹脂浸入40 ml六氫吡啶: DMF溶液(20:80 v/v)達20 min來實施Fmoc去保護。藉由在0.1 M於DMF中之Fmoc-胺基酸濃度下，用DMF中之4莫耳當量Fmoc-胺基酸、4莫耳當量HBTU及10莫耳當量二異丙基乙胺將樹脂浸泡40分鐘來實施醯胺偶合。使用Fmoc-Dap(DNP)-OH以將DNP發色團附接至樹脂，並自Dap α-胺合成肽。自樹脂之解離係在三氟乙酸溶液中實施2小時。經由使用Et2
O沈澱之壓縮空氣將溶劑降低至原始體積之10%。經由TFA之微解離及分析HPLC證實產物之屬性。然後使用以約1 ml/min之線性梯度溶析之Supelco 「Discovery BIO」大孔C18管柱(25 cm × 21 mm，10 um顆粒)利用製備級Shimadzu HPLC將肽純化至＞ 95%純度。使用配備有Waters XBridge BEH130 C18管柱(250 mm × 6.6 mm, 5 μm顆粒)之分析型Shimadzu HPLC，使用10-90% B溶劑經50分鐘評價純度。A溶劑表示H2
O:F3
CCO2
H 100:0.1 v/v，B溶劑表示CH3
CN: F3
CCO2
H 100:0.1 v/v。
Fmoc-Dap(DNP)-OH實例 2. 血清穩定性 .
藉由在小鼠血清中培育αvβ6配位子並分析未消化之肽在不同時間點之百分比來測試αvβ6配位子之血清穩定性。藉由分析型HPLC測定未消化之αvβ6配位子。藉由在＞10 mg/ml之濃度下將肽溶解於H2
O中來製備αvβ6配位子之個別原液。使用UV/Vis吸收(DNP: λ=365，ϵ=17300 M-1
Cm-1
)來評價αvβ6配位子之濃度。將αvβ6配位子稀釋至1 mg/ml於90%小鼠血漿中之配位子並置於37℃下之培育器中。在給定之時間點(指定時間點)，使用10%-90%B
溶劑經50分鐘將試樣注射至配備有Waters XBridge BEH130 C18管柱(250 mm × 6.6 mm，5 μm顆粒)之分析型HPLC (Shimadzu HPLC)上。A
溶劑表示H2
O:F3
CCO2
H 100:0.1 v/v，B
溶劑表示CH3
CN: F3
CCO2
H 100:0.1 v/v。 使用以下等式計算血清培育後剩餘之配位子百分比： 剩餘% = [(t=x 時之面積
) ÷ (t=0 時之面積
)] × 100% 其中t=0時之面積係將配位子稀釋於血漿中後即刻之配位子峰下之面積，且t=x時之面積係在時間= x時肽峰下之面積。 將各肽共價連接至貨物分子PEG8
-Dap(DNP)，然後使用PEG8
-Dap(DNP)來促進分析。
胺端帽(Z)之存在亦提供增加之血清穩定性。非標準胺基酸在Xaa1
、Xaa2
及/或Y之存在亦提供增加之血清穩定性。 表. αvβ6配位子之血清穩定性。將肽衍生物連接至貨物分子PEG8
-Dap(DNP)並在37℃下在小鼠血清中培育4、8、12或24小時。藉由HPLC量測肽衍生物穩定性。胺端帽及Xaa1
Xaa2
加下劃線。 
實例 3. 整合素結合 A. αvβ6 配位子 - 貨物分子偶聯 .
將各αvβ6配位子附接至經可逆修飾之APN1170-100B聚合物貨物分子。將APN1170-100B(56:44乙氧基乙胺丙烯酸酯: MW為約45000之丙烯酸丙酯共聚物)用Cy5 (NHS連接體)標記，並在RT下與醛-PEG24
-ACit以2:1(聚合物:醛-PEG24
-ACit)之重量比在50 mM HEPES pH 9.0緩衝液中合併1 h，以形成(醛-PEG24
-ACit)n
-APN1170-100B，其中n係大於0之整數。通常n係約10。
醛-PEG24
-ACit (n = 24) 然後在RT下使醛-PEG24
-ACit-修飾之聚合物與PEG12
-ACit以1:8 (聚合物:PEG12
-ACit)之重量比在50 mM HEPES pH 9.0緩衝液中反應1 h，以形成(醛-PEG24
-ACit)n
-APN1170-100B-(CitA-PEG12
)m
，其中m係大於0之整數。
PEG12-ACit (n = 11) 然後使用sephadex G-50離心管純化經修飾之聚合物並測定濃度：
用HyNic將各αvβ6配位子修飾以促進與貨物分子之偶聯。在RT下，將經純化之聚合物與αvβ6配位子-(PEG)8
-K-HyNic以1:1.9 (聚合物: αvβ6配位子)之重量比在50 mM NaOAC-HOAc pH 5.0緩衝液中合併過夜，以形成αvβ6配位子-聚合物偶聯物。使用sephadex G-50離心管來純化αvβ6配位子-聚合物偶聯物。
(PEG)8
-K-HyNic
αvβ6配位子-(PEG)8
-K-HyNic 使用對於雙-芳基腙鍵2.9×101
M-1
cm-1
之消光係數，藉由量測αvβ6-聚合物偶聯物在354 nm之吸光度來定量偶聯效率。
用等滲葡萄糖溶液將αvβ6-聚合物偶聯物稀釋至期望之濃度用於進一步分析。 B.αvβ6 配位子結合( 流式細胞計數分析 ).
為評價αvβ6配位子與αvβ6整合素結合之特異性，將各αvβ6配位子或陰性對照肽偶聯至經Cy5標記之聚合物(如上文所述)並評估投與細胞之結合。HUH7 (人類肝細胞癌)及SKOV3 (人類卵巢癌)細胞經測定展現極低之αvβ6細胞表面表現，並使用其作為陰性對照細胞系。使用H2009 (人類肺上皮腺癌)及CAPAN-2 (人類胰臟腺癌)細胞作為αvβ6陽性對照細胞系。利用Accutase將細胞自培養瓶分離，在PBS中洗滌並以200 μl完全培養基(具有補料及胎牛血清之培養基)中之200,000個細胞接種於5 ml聚苯乙烯圓底管中。以5 μg/ml (聚合物-Cy5濃度)將αvβ6配位子-聚合物偶聯物或無配位子-聚合物偶聯物添加至細胞，混合並在37℃下培育3 h。在37℃下培育促進配位子/受體相互作用，其可導致靜態結合至細胞外細胞表面及/或內化之配位子/受體複合體。將混合物以1 h間隔重新懸浮。在3 h之培育後，用4 ml冷凍懸浮液(PBS-2% FCS)將細胞洗滌2×，並重新懸浮在200 μl含有10 μM SYTOX青變之緩衝液中用於活/死細胞選通。在配備有紫色(405nm)、藍色(488nm)及紅色(633nm)雷射之BD Biosciences Canto II細胞計數器上分析試樣。最初在具有紫色雷射之C檢測器上將活細胞選通為SYTOX藍色陰性群體。然後利用紅色雷射將該等活細胞之偶聯物結合/攝取評價為Cy5螢光團之平均螢光強度(MFI)。利用FlowJo v10.1軟體實施數據分析。藉由下式確定各αvβ6配位子之特異性MFI比率(sMFIr)： 特異性試樣MFI值/無配位子MFI值。 僅肽Ac-RGDLAAbuL-CitAibL顯示與SKOV3細胞之適度結合。此肽顯示不與HUH7細胞顯著結合。因此，所測試之肽皆不展現非特異性結合。不含有RGD之陰性對照肽、AcRGαMeDLAAbuLCitAib、AcRGDαMeLAAbuLCitAib、RGELATLRQL、AcCitGDLATLCitQL、AcK(Me)2
GDLATLRQL及AcR(Me)2
GDLATLRQL未顯示與H2009或CAPAN-2 αvβ6整合素-陽性對照細胞之顯著結合，此指示對於αvβ6整合素無親和性。大部分其他肽顯示與H2009或CAPAN-2細胞之結合相當於或高於親本肽RGDLATLRQL及RGDLATL，此指示對於αvβ6整合素之良好親和性。 表. 結合至表現αvβ6整合素之細胞(H2009及CAPAN-2)及不表現αvβ6整合素之細胞(HUH7及SKOV3)之αvβ6配位子。 
Aib係α-胺基-異丁酸 Cit係瓜胺酸
Abu係L-α-胺基-丁酸 αMeD係α-甲基-天冬胺酸鹽
αMeL係α-甲基-L-白胺酸 Cha係β-環己基-丙胺酸
Nva係正纈胺酸 K(Me)2
係N,N-ε-二甲基離胺酸
R(Me)2
係二甲基精胺酸 Dap (Ac)
Dap (胍基) NMe
G係N-甲基-甘胺酸
NMe
L係N-甲基白胺酸 脫胺基-R係脫胺基-精胺酸
β3-hA係β-高丙胺酸 間胍基-苯甲酸
胍基-R係胍基-精胺酸 MeO-PEG8
圖1提供本發明αvβ1配位子之實例。
<110> 美商愛羅海德製藥公司(Arrowhead Pharmaceuticals,Inc.)
<120> α-V β-6整合素配位子
<130> 30639-WO1
<140> 106137824
<141> 2017-11-01
<150> US 62/415,752
<151> 2016-11-01
<160> 84
<210> 1
<211> 10
<212> PRT
<213> 天然序列
<400> 1
<210> 2
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<400> 2
<210> 3
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 3
<210> 4
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 4
<210> 5
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 5
<210> 6
<211> 8
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<400> 6
<210> 7
<211> 7
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<400> 7
<210> 8
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<400> 8
<210> 9
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<400> 9
<210> 10
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<400> 10
<210> 11
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<400> 11
<210> 12
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<400> 12
<210> 13
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 13
<210> 14
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 14
<210> 15
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 15
<210> 16
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 16
<210> 17
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 17
<210> 18
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3CH2CO
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 18
<210> 19
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3(CH2)2CO
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 19
<210> 20
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3(CH2)3CO
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 20
<210> 21
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3(CH2)4CO
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 21
<210> 22
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 22
<210> 23
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 23
<210> 24
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 24
<210> 25
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 25
<210> 26
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 26
<210> 27
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 27
<210> 28
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 28
<210> 29
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 29
<210> 30
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 30
<210> 31
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 31
<210> 32
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 32
<210> 33
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<400> 33
<210> 34
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa=α-甲基-天冬胺酸鹽
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 34
<210> 35
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa=α-甲基-白胺酸
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 35
<210> 36
<211> 8
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Aib
<400> 36
<210> 37
<211> 10
<212> PRT
<213> 天然序列
<400> 37
<210> 38
<211> 14
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> C-末端HyNic
<400> 38
<210> 39
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端間胍基-苯甲酸
<400> 39
<210> 40
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> C-末端Me
<400> 40
<210> 41
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端胍基
<400> 41
<210> 42
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端MeO-PEG8
<400> 42
<210> 43
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<400> 43
<210> 44
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<400> 44
<210> 45
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<400> 45
<210> 46
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<400> 46
<210> 47
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa=Cit
<400> 47
<210> 48
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<400> 48
<210> 49
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<400> 49
<210> 50
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Abu
<400> 50
<210> 51
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 51
<210> 52
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Dap(Ac)
<400> 52
<210> 53
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Cit
<400> 53
<210> 54
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Nva
<400> 54
<210> 55
<211> 10
<212> PRT
<213> 天然序列
<400> 55
<210> 56
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa=N,N-ε-二甲基離胺酸
<400> 56
<210> 57
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa=二甲基精胺酸
<400> 57
<210> 58
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Dap(胍基)
<400> 58
<210> 59
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端脫胺基
<400> 59
<210> 60
<211> 11
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=β-高丙胺酸
<400> 60
<210> 61
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa=Aib
<400> 61
<210> 62
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa=β-環己基丙胺酸
<400> 62
<210> 63
<211> 9
<212> PRT
<213> 天然序列
<400> 63
<210> 64
<211> 8
<212> PRT
<213> 天然序列
<400> 64
<210> 65
<211> 7
<212> PRT
<213> 天然序列
<400> 65
<210> 66
<211> 6
<212> PRT
<213> 天然序列
<400> 66
<210> 67
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa=Aib
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 67
<210> 68
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa=β-高丙胺酸
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 68
<210> 69
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa=β-環己基丙胺酸
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 69
<210> 70
<211> 10
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa=N-甲基-甘胺酸
<400> 70
<210> 71
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa=N-甲基-甘胺酸
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 71
<210> 72
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa=N-甲基白胺酸
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 72
<210> 73
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (7)..(7)
<223> Xaa=N-甲基白胺酸
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 73
<210> 74
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3CH2
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 74
<210> 75
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3(CH2)2
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 75
<210> 76
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3(CH2)3
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 76
<210> 77
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3(CH2)4
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 77
<210> 78
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 78
<210> 79
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端Ac
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 79
<210> 80
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3(CH2)lCO
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 80
<210> 81
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3O(CH2CH2O)lCH2CH2CO
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 81
<210> 82
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3O(CH2CH2O)2CH2CH2CO
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 82
<210> 83
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3O(CH2CH2O)3CH2CH2CO
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 83
<210> 84
<211> 9
<212> PRT
<213> 人工序列
<220>
<221> misc_feature
<222> (1)..(1)
<223> N-末端CH3O(CH2CH2O)5CH2CH2CO
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa=Abu
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa=Cit
<220>
<221> misc_feature
<222> (9)..(9)
<223> Xaa=Aib
<400> 84
Claims (14)
- 一種αvβ6整合素配位子，其包含：RG1DLXaa1Xaa2L-Xaa3Xaa4L-R1(SEQ ID NO：96)(Formula VIII)其中R係L-精胺酸；G1係L-甘胺酸或N-甲基甘胺酸；D係L-天冬胺酸(L-天冬胺酸鹽)；L係L-白胺酸；Xaa1係L-丙胺酸；Xaa2係L-α-胺基丁酸(Abu)；Xaa3係瓜胺酸(Cit)；Xaa4係胺基異丁酸(Aib)；且R1係不存在或存在，且若存在，則包含PEG及/或連接基團。
- 如請求項1之αvβ6整合素配位子，其中R1包含具有2至20個環氧乙烷單元之聚乙二醇。
- 如請求項1或2之αvβ6整合素配位子，其中該αvβ6整合素配位子包含胺端帽。
- 如請求項1或2之αvβ6整合素配位子，其中該胺端帽係選自由以下組成之群：CH3CO、CH3CH2CO、CH3(CH2)2CO、(CH3)2CHCO、CH3(CH2)3CO、 (CH3)2CHCH2CO、CH3CH2CH(CH3)CO、(CH3)3CCO、CH3(CH2)4CO、CH3SO2、CH3CH2SO2、CH3(CH2)2SO2、(CH3)2CHSO2、CH3(CH2)3SO2、(CH3)2CHCH2SO2、CH3CH2CH(CH3)SO2、(CH3)3CSO2、PhCO、PhSO2、具有1、2、3、4、5、6、7、8、9或10個碳原子之烷基、甲基、乙基、丙基、丁基、戊基、NH2NH、PEG、胍基、CH3OCH2CH2OCH2CH2CO、CH3O(CH2CH2O)2CH2CH2CO、CH3O(CH2CH2O)3CH2CH2CO、CH3O(CH2CH2O)4CH2CH2CO、CH3O(CH2CH2O)5CH2CH2CO、CH3OCH2CH2OCH2CO、CH3O(CH2CH2O)2CH2CO、CH3O(CH2CH2O)3CH2CO、CH3O(CH2CH2O)4CH2CO、CH3O(CH2CH2O)5CH2CO、CH3OCH2CH2OCO、CH3O(CH2CH2O)2CO、CH3O(CH2CH2O)3CO、CH3O(CH2CH2O)4CO、CH3O(CH2CH2O)5CO、HOCH2CH2OCH2CH2CO、HO(CH2CH2O)2CH2CH2CO、HO(CH2CH2O)3CH2CH2CO、HO(CH2CH2O)4CH2CH2CO、HO(CH2CH2O)5CH2CH2CO、HOCH2CH2OCH2CO、HO(CH2CH2O)2CH2CO、HO(CH2CH2O)3CH2CO、HO(CH2CH2O)4CH2CO、HO(CH2CH2O)5CH2CO、HOCH2CH2OCO、HO(CH2CH2O)2CO、HO(CH2CH2O)3CO、HO(CH2CH2O)4CO、HO(CH2CH2O)5CO、CH3CH2OCH2CH2OCH2CH2CO、CH3CH2O(CH2CH2O)2CH2CH2CO、CH3CH2O(CH2CH2O)3CH2CH2CO、CH3CH2O(CH2CH2O)4CH2CH2CO、CH3CH2O(CH2CH2O)5CH2CH2CO、CH3CH2OCH2CH2OCH2CO、CH3CH2O(CH2CH2O)2CH2CO、CH3CH2O(CH2CH2O)3CH2CO、CH3CH2O(CH2CH2O)4CH2CO、CH3CH2O(CH2CH2O)5CH2CO、CH3CH2OCH2CH2OCO、CH3CH2O(CH2CH2O)2CO、CH3CH2O(CH2CH2O)3CO、CH3CH2O(CH2CH2O)4CO、CH3CH2O(CH2CH2O)5CO、CH3OCH2CH2CO、 HOCH2CH2CO或CH3CH2OCH2CH2CO。
- 如請求項4之αvβ6整合素配位子，其中該胺端帽係CH3CO。
- 如請求項1之αvβ6整合素配位子，其中該αvβ6整合素配位子包含SEQ ID NO：4之序列(Ac-RGDLAAbuLCitAibL)。
- 如請求項1或2之αvβ6整合素配位子，其中該αvβ6整合素配位子進一步偶聯至貨物分子。
- 如請求項1或2之αvβ6整合素配位子，其中該αvβ6整合素配位子偶聯至包含以下之貨物分子：小分子、抗體、抗體片段、免疫球蛋白、單株抗體、標記或標記物、脂質、天然或經修飾之核酸或多核苷酸、肽、適體、聚合物、多胺、蛋白質、毒素、維生素、聚乙二醇、半抗原、地谷新配質(digoxigenin)、生物素、放射性原子或分子或螢光團。
- 如請求項1或2之αvβ6整合素配位子，其中該αvβ6整合素配位子偶聯至包含活性醫藥成分之貨物分子。
- 如請求項1或2之αvβ6整合素配位子，其中該αvβ6整合素配位子偶聯至包含寡聚化合物之貨物分子。
- 如請求項10之αvβ6整合素配位子，其中該寡聚化合物係RNAi藥劑。
- 一種組合物，其包含如請求項1至11中任一項之αvβ6整合素配位子及醫藥上可接受之賦形劑。
- 一種偶聯至寡聚化合物之如請求項1之αvβ6整合素配位子之用途，其係用以製備藉由抑制細胞中靶點基因之表現治療癌症之藥物。
- 如請求項13之用途，其中該寡聚化合物係RNAi藥劑。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415752P | 2016-11-01 | 2016-11-01 | |
| US62/415,752 | 2016-11-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201829445A TW201829445A (zh) | 2018-08-16 |
| TWI776821B true TWI776821B (zh) | 2022-09-11 |
Family
ID=62076333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106137824A TWI776821B (zh) | 2016-11-01 | 2017-11-01 | α-V β-6整合素配位子 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11180529B2 (zh) |
| EP (2) | EP3981780A1 (zh) |
| JP (2) | JP7291624B2 (zh) |
| KR (1) | KR102634762B1 (zh) |
| CN (2) | CN117285626A (zh) |
| AU (2) | AU2017354041B2 (zh) |
| BR (1) | BR112019008965A2 (zh) |
| CA (1) | CA3039618A1 (zh) |
| DK (1) | DK3535397T3 (zh) |
| EA (1) | EA201991102A1 (zh) |
| ES (1) | ES2906109T3 (zh) |
| HR (1) | HRP20220181T1 (zh) |
| IL (2) | IL266343B2 (zh) |
| JO (1) | JOP20190084B1 (zh) |
| MX (3) | MX2019004909A (zh) |
| PL (1) | PL3535397T3 (zh) |
| SA (1) | SA519401709B1 (zh) |
| SI (1) | SI3535397T1 (zh) |
| TW (1) | TWI776821B (zh) |
| WO (1) | WO2018085415A1 (zh) |
| ZA (1) | ZA201901905B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7291624B2 (ja) * | 2016-11-01 | 2023-06-15 | アローヘッド ファーマシューティカルズ インコーポレイテッド | アルファ－ｖベータ－６インテグリンリガンド及びその使用 |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN |
| KR20200024793A (ko) | 2017-07-06 | 2020-03-09 | 애로우헤드 파마슈티컬스 인코포레이티드 | 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법 |
| MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
| KR102663798B1 (ko) | 2019-06-25 | 2024-05-03 | 주식회사 엘지에너지솔루션 | 배터리 시스템 |
| EP4211243A2 (en) | 2020-09-11 | 2023-07-19 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use |
| CN116783294A (zh) * | 2020-09-11 | 2023-09-19 | 箭头药业股份有限公司 | 整联蛋白靶向配体及其用途 |
| WO2022056269A1 (en) * | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Skeletal muscle delivery platforms and methods of use |
| WO2024006999A2 (en) | 2022-06-30 | 2024-01-04 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150125392A1 (en) * | 2005-10-03 | 2015-05-07 | Cancer Research Technology Limited | AVß6 PEPTIDE LIGANDS AND THEIR USES |
| WO2015160770A1 (en) * | 2014-04-15 | 2015-10-22 | The Regents Of The University Of California | Bi-terminal pegylated integrin-binding peptides and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| DE19929410A1 (de) * | 1999-06-26 | 2000-12-28 | Merck Patent Gmbh | Inhibitoren des Integrins avß6 |
| JP2003530871A (ja) * | 2000-04-21 | 2003-10-21 | アムジエン・インコーポレーテツド | インテグリン／接着因子アンタゴニスト |
| DE10118550A1 (de) * | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Liganden des Integrins alpha¶nu¶beta¶6¶ |
| AU2007348941B2 (en) * | 2006-08-03 | 2011-08-04 | Medimmune Limited | Antibodies directed to alphaVbeta6 and uses thereof |
| AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
| EP2221334B1 (en) | 2007-11-28 | 2016-12-28 | FUJIFILM Corporation | Method for chemically modifying biopolymer and polypeptide |
| JP6173216B2 (ja) * | 2010-11-26 | 2017-08-02 | モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ | 設計アンキリンリピートタンパク質のための改善されたキャッピングモジュール |
| CN104220094A (zh) * | 2012-02-17 | 2014-12-17 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
| US10073109B2 (en) * | 2015-04-06 | 2018-09-11 | The Board Of Regents Of The University Of Oklahoma | Phages of biomarker capture and methods of use |
| EP3130912B1 (de) | 2015-08-14 | 2017-06-28 | Sick Ag | Verfahren zur bestimmung der konzentration einer gaskomponente und spektrometer dafür |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| JP7291624B2 (ja) * | 2016-11-01 | 2023-06-15 | アローヘッド ファーマシューティカルズ インコーポレイテッド | アルファ－ｖベータ－６インテグリンリガンド及びその使用 |
-
2017
- 2017-11-01 JP JP2019522676A patent/JP7291624B2/ja active Active
- 2017-11-01 EA EA201991102A patent/EA201991102A1/ru unknown
- 2017-11-01 MX MX2019004909A patent/MX2019004909A/es unknown
- 2017-11-01 JO JOP/2019/0084A patent/JOP20190084B1/ar active
- 2017-11-01 EP EP21202340.2A patent/EP3981780A1/en active Pending
- 2017-11-01 EP EP17867252.3A patent/EP3535397B1/en active Active
- 2017-11-01 AU AU2017354041A patent/AU2017354041B2/en active Active
- 2017-11-01 TW TW106137824A patent/TWI776821B/zh active
- 2017-11-01 WO PCT/US2017/059550 patent/WO2018085415A1/en active Application Filing
- 2017-11-01 IL IL266343A patent/IL266343B2/en unknown
- 2017-11-01 CN CN202311057967.9A patent/CN117285626A/zh active Pending
- 2017-11-01 CA CA3039618A patent/CA3039618A1/en active Pending
- 2017-11-01 CN CN201780068077.4A patent/CN109952376B/zh active Active
- 2017-11-01 SI SI201731066T patent/SI3535397T1/sl unknown
- 2017-11-01 DK DK17867252.3T patent/DK3535397T3/da active
- 2017-11-01 HR HRP20220181TT patent/HRP20220181T1/hr unknown
- 2017-11-01 PL PL17867252T patent/PL3535397T3/pl unknown
- 2017-11-01 IL IL305158A patent/IL305158A/en unknown
- 2017-11-01 KR KR1020197012274A patent/KR102634762B1/ko active IP Right Grant
- 2017-11-01 ES ES17867252T patent/ES2906109T3/es active Active
- 2017-11-01 BR BR112019008965A patent/BR112019008965A2/pt unknown
-
2019
- 2019-03-27 ZA ZA2019/01905A patent/ZA201901905B/en unknown
- 2019-04-26 MX MX2023007046A patent/MX2023007046A/es unknown
- 2019-04-26 MX MX2023007051A patent/MX2023007051A/es unknown
- 2019-04-30 US US16/399,073 patent/US11180529B2/en active Active
- 2019-05-01 SA SA519401709A patent/SA519401709B1/ar unknown
-
2021
- 2021-10-14 US US17/501,486 patent/US20220024975A1/en not_active Abandoned
-
2023
- 2023-06-02 JP JP2023091857A patent/JP2023105046A/ja active Pending
-
2024
- 2024-04-24 AU AU2024202695A patent/AU2024202695A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150125392A1 (en) * | 2005-10-03 | 2015-05-07 | Cancer Research Technology Limited | AVß6 PEPTIDE LIGANDS AND THEIR USES |
| WO2015160770A1 (en) * | 2014-04-15 | 2015-10-22 | The Regents Of The University Of California | Bi-terminal pegylated integrin-binding peptides and methods of use thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI776821B (zh) | α-V β-6整合素配位子 | |
| US11840581B2 (en) | α4β7 thioether peptide dimer antagonists | |
| US10278957B2 (en) | Opioid agonist peptides and uses thereof | |
| US11753443B2 (en) | Conjugated hepcidin mimetics | |
| AU2002306500C1 (en) | Transporters comprising spaced arginine moieties | |
| US9102710B2 (en) | Cyclic peptides binding CXCR4 receptor and relative medical and diagnostic uses | |
| JP2018123169A (ja) | ヘプシジン類似体及びその使用 | |
| CN111741771A (zh) | 特异于epha2的双环肽配体 | |
| BR112017008575B1 (pt) | Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica | |
| US20210101932A1 (en) | Bicyclic peptide ligands specific for pd-l1 | |
| AU2016232833A1 (en) | Selective Mcl-1 binding peptides | |
| WO2021167107A1 (ja) | ヒトトランスフェリンレセプター結合ペプチド | |
| ES2273703T3 (es) | Derivados peptidos ciclicos como inhibidores derivados del alfa v y beta 6 de la integrina. | |
| CN109563135B (zh) | α(V)β(6)整合素结合肽及其使用方法 | |
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| US6207639B1 (en) | Compounds and methods for modulating neurite outgrowth | |
| US20180371018A1 (en) | Polypeptide compound, preparation method therefor and use thereof | |
| US20170333549A1 (en) | Hemagglutinin-Binding Peptide | |
| US20230287051A1 (en) | Inhibitors of complement factor c3 and their medical uses | |
| US20230242582A1 (en) | Novel alpha-helical double-sided cell penetrating peptide and use thereof | |
| JP2003503422A (ja) | インテグリンαｖβ６の阻害剤 | |
| EP3981784A1 (en) | Regulators of cell division | |
| CA3228449A1 (en) | Human transferrin receptor binding peptide | |
| WO2018106937A1 (en) | Compositions and methods for inhibition of foxp3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent |